Category survey

The importance of phosphorylation in modulating Hsp70 function; potential for novel therapeutic strategies for cancer and amyloid diseases Investments < €500k Ireland 2016    

The mechanism of binding of drug candidates to disordered proteins Investments < €500k Hungary 2016    

Coordination and electrochemical background of role of metal ions in neurodegenerative disorders Investments < €500k Hungary 2016    

Neuroprotective mechanisms of non-classical estrogen-like signaling activators in basal forebrain cholinergic neurons: testing of novel compounds Investments < €500k Hungary 2016    

Secondary structure determination and protein fold prediction by CD spectroscopy: method development and its application on aberrant protein aggregates and amyloid fibrils Investments < €500k Hungary 2016    

INVOLVEMENT OF TUBULIN POLYMERIZATION PROMOTING PROTEIN (TPPP/p25) IN NEUROPROTECTION ACHIEVED BY AUTOPHAGY, PROTEASOME AND AGGRESOME SYSTEMS Dissection of peptidomimetic foldamer for potential anti-synucleinopathy drugs Investments < €500k Hungary 2016    

Physiological and pathological interactions of the disordered TPPP/p25: mapping of binding motifs Investments < €500k Hungary 2016    

Specific histone modifications in the pathogenesis of Huntington’s disease Investments < €500k Hungary 2016    

The role of Hsp27 in neurodegenerative diseases from the aspects of membranes and lipids Investments < €500k Hungary 2016    

Deep brain stimulation: a new way of understanding the human brain Investments < €500k Hungary 2016    

Identification and characterization of diagnostic biomarkers in Alzheimer’s disease and in prodormal stadium Investments < €500k Hungary 2016    

The role of epigenetic factors and non-coding RNA in Parkinson’s disease Investments < €500k Hungary 2016    

The connection of MERTK, TSP-1, BDNF, ACE and NOS3 polymorphism with age related macular degeneration and Alzheimer’s disease Investments < €500k Hungary 2016    

The relation between epilepsy and Alzheimer’s disease Investments < €500k Hungary 2016    

The validation of new pharmacological strategies in schizophrenia and dementia models Investments < €500k Hungary 2016    

The TRPA1 receptor, as potential target in neurodegenerative and inflammatory diseases, and cognitive disorders Investments < €500k Hungary 2016    

The role of PACAP in Parkinson’s disease Investments < €500k Hungary 2016    

New experimental model development to test procognitive and neuroprotective compounds Investments < €500k Hungary 2016    

Tryptophan metabolites and kynurenic acid analogs in cognitive decline Investments < €500k Hungary 2016    

Neurocognitive disorders of the frontostriatal system Investments < €500k Hungary 2016    

Immunotherapy of familial prion diseases Investments < €500k Germany 2016    

Uncertainty monitoring versus inhibition control: The role of subclude nuclues and effects of deep brain stimulation on oscillatory neuronal networks in Parkinson’s disease compared to compulsive disorder Investments < €500k Germany 2016    

Description of causes of neurodegenerative disease mechanisms by producing amyloid beta aggregates from synthetic and patient material Investments < €500k Germany 2016    

Biopharmaceutical Neurology: Blood Assay for the Predictive and Early Diagnosis of Alzheimer’s Disease Investments < €500k Germany 2016    

Multimodal biomarkers for the longer-term prediction and staging of a probable Alzheimer’s disease in pre-dementia conditions Investments < €500k Germany 2016    

Molecular analysis of neurodegeneration and muscular atrophy in amyotrophic lateral sclerosis Investments < €500k Germany 2016    

Development of a new blood test for the diagnosis of Alzheimer’s disease Investments < €500k Germany 2016    

Development of a blood-based early diagnosis of Alzheimer’s dementia Investments < €500k Germany 2016    

New therapeutic approaches for multiple system atrophy with starting point alpha-synuclein Investments < €500k Germany 2016    

Monitoring and evaluation of local alliances for people with dementia Investments < €500k Germany 2016    

What’s going on! Sports and dementia Investments < €500k Germany 2016    

Single cell genomics in the brain in healthy humans and in patients with neurodegenerative diseases Investments < €500k Germany 2016    

Dementia for people with learning difficulties Investments < €500k Germany 2016    

Guidepost dementia Investments < €500k Germany 2016    

Local alliances for people with dementia “committed locally and sustainably” Investments < €500k Germany 2016    

Future workplace dementia Investments < €500k Germany 2016    

Towards in vivo molecular imaging of α synuclein protein Investments < €500k France 2016    

Predict-PGRN- Caractérisation multimodale prospective de la démence frontotemporale dûe à des mutations du gène PGRN à un stade symptomatique et présymptomatique / PREDICT. Predict-PGRN- Prospective multimodal characterization of frontotemporal dementia due to mutations of the PGRN gene at a symptomatic…

Vieillissement pathologique et non-pathologique, Activité physique, Génotype et Cognition / ViAGeCo. Pathological and non-pathological aging, Physical activity, Genotype and Cognition / ViAGeCo Investments < €500k France 2016    

Comment proches et professionnels communiquent avec les personnes atteintes de la maladie d’Alzheimer. Apprentissage et diversité des compétences communicationnelles. How close and professional are communicating with people with Alzheimer’s disease. Learning and diversity of communication skills Investments < €500k France…

La décision médicale et ses enjeux éthiques dans la relation de soin avec des malades d’Alzheimer et apparentés. The medical decision and its ethical stakes in the care relationship with Alzheimer’s and related patients Investments < €500k France 2016  …

Les dispositifs électroniques de géolocalisation destinés aux malades d’Alzheimer et maladies apparentées : production, usages et régulation. Electronic geolocation devices for Alzheimer’s and related diseases: production, use and regulation. Investments < €500k France 2016    

Dynamique et recomposition professionnelles au tour de la maladie d’Alzheimer. Analyse qualitative du rôle des professionnels du soin, des nouveaux professionnels et des dispositifs créés par la Plan Alzheimer. Professional dynamics and recomposition in the turn of Alzheimer’s disease. Qualitative…

Analyse juridique de la capacité des personnes atteintes de maladie d’Alzheimer. Legal analysis of the capacity of people with Alzheimer’s disease Investments < €500k France 2016    

AMYGING Longitudinal Study of Brain Amyloid imaGing in MEMENTO (MEMENTOAmyGing) Investments < €500k France 2016    

Biological and mathematical modelization of amyloid origin, spreading and impact on brain function Investments < €500k France 2016    

Role of astrocytic 3-phosphoglycerate dehydrogenase in AD Investments < €500k France 2016    

Human iPSCs-derived neuron-astrocyte co-culture as an innovative strategy to study the role of astrocytes in Alzheimer’s disease Investments < €500k France 2016    

Impairment of Synaptic Vesicles function in Alzheimer Disease Investments < €500k France 2016    

Contributions of amino- and dipeptidyl-peptidases-mediated truncations of amyloid peptides to Alzheimer’s disease: a combined cellular and in vivo approach Investments < €500k France 2016